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The discovery of novel mechanism of action (MOA) antibacterials has been associated with the concept
that antibacterial drugs occupy a differentiated region of physicochemical space compared to human-
targeted drugs. With, in broad terms, antibacterials having higher molecular weight, lower logP and
higher polar surface area (PSA). By analysing the physicochemical properties of about 1700 approved
drugs listed in the ChEMBL database, we show, that antibacterials for whose targets are riboproteins
(i.e., composed of a complex of RNA and protein) fall outside the conventional human ‘drug-like’ chemical
space; whereas antibacterials that modulate bacterial protein targets, generally comply with the ‘rule-
of-ﬁve’ guidelines for classical oral human drugs. Our analysis suggests a strong target-class association
for antibacterials—either protein-targeted or riboprotein-targeted. There is much discussion in the liter-
ature on the failure of screening approaches to deliver novel antibacterial lead series, and linkage of this
poor success rate for antibacterials with the chemical space properties of screening collections. Our anal-
ysis suggests that consideration of target-class may be an underappreciated factor in antibacterial lead
discovery, and that in fact bacterial protein-targets may well have similar binding site characteristics
to human protein targets, and questions the assumption that larger, more polar compounds are a key part
of successful future antibacterial discovery.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The discovery of antibacterial agents, such as the aminoglyco-
sides, streptogramins, tetracyclines, b-lactams, and quinolones,
from the 1930s onwards1 brought signiﬁcant relief to the health
burden caused by pathogenic bacteria worldwide. Nevertheless,
the success of antibacterial chemotherapy is now being signiﬁ-
cantly challenged by the emergence of drug-resistant bacterial
strains, poor hit rates from genomics/target-led screens2 and high
drug failure rates in late clinical development.3 Treatment of bac-
terial infectious diseases is also often complicated by comorbidity,
for example, co-infection with human immunodeﬁciency virus
(HIV), extended duration of chemotherapy and diagnostic delays.4
Drug-resistant strains have a direct impact on the clinical treat-
ment of diseases such as leprosy, Staphylococcus, Strepto- and
Enterococcus, Clostridia, and Pseudomonas, and arguably most sig-
niﬁcantly on tuberculosis (TB).
Tuberculosis and leprosy are mycobacterial diseases affecting
substantial parts Africa, the Americas, South-East Asia, the
Eastern Mediterranean and the Western Paciﬁc Regions andtogether cause close to a million deaths every year.5,6 To curb the
development of resistance to rifampicin, multidrug therapy
(MDT) is often used, where the drug is used in combination with
other antibacterials. MDT has been successful as evidenced by
the decrease in the number of reported leprosy or TB cases but it
increases the drug burden on the patient, and could lead to non-
compliance and the eventual emergence of resistance. In the indus-
trialised Northern hemisphere drug resistance, for example with
hospital-acquired methicillin-resistant Staphylococcus aureus
(MRSA), is also perceived as a major societal threat. The aforemen-
tioned challenges call for continual discovery and development of
new mechanism differentiated antibacterials. These drugs would
potentially be less prone to resistance (or at least have
distinguished resistance proﬁles), have newmodes of action and/or
targets and with the capability to reduce drug load.
Advances in technologies in genomics and sequencing, high-
throughput screening (HTS), automated chemical synthesis and
structural biology, have so far had limited direct impact on the dis-
covery of new classes of drugs; it has taken more than four decades
for the novel linezolid class of antibacterial drugs (2000), to be
approved7,1, and more recently bedaquiline (2012) for treatment
of drug-resistant tuberculosis.8 This productivity challenge has
drawn researchers in industry and academia, and more recently
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approaches to antibacterial discovery. Examples include identiﬁca-
tion ofwhole cell-basedmethods to identify antibacterial leadswith
the ability to penetrate the bacterial cell wall, in conjunction with
currently used target-based approaches. Furthermore, the consider-
ation of the physicochemical properties of the chemical compounds
during the early stages of drug discovery process9,1,10 has helped to
avoid failure in Phases II/III of clinical development. Experimental
and computational approaches have therefore been used to analyse
the historical physicochemical properties of drugs and to develop
models used in determining drug-like compounds, and in some
cases, propose biased or focussed properties for antibacterials.11
Study of the properties of approved drug structures in the
1990’s led to the concept of a restricted range of physicochemical
parameters that appeared optimal for orally administered drugs—
many researchers have used the ‘rule of ﬁve’12 as a guide for
‘drug-like’ compounds during screening and structure modiﬁcation
of leads to optimise their potency, metabolism and exposure. The
‘rule of ﬁve’ states that good absorption is more likely when an
orally administered compound has less than ﬁve hydrogen-bond
donors, molecular weight <500 Da, c logP <5, and less than 10
hydrogen-bond acceptors.12,13 Later it was also observed that polar
surface area (PSA) and a logP could predict with 95% conﬁdence
that a test compound would have high or low (90% or 30%,
respectively) intestinal absorption in humans.14 For high absorp-
tion the upper limits were, PSA 131.6 Å2, and a logP of 5.88.
Veber et al.15 suggested that compounds with 10 or less rotatable
bonds and PSA less than or equal to 140 Å2 (or 12 or fewer hydro-
gen-bond donors or acceptors) would have good oral availability in
rats. A number of authors subsequently reported that approved
antibacterial agents often violated Lipinski’s ‘rule of ﬁve’, with
antibacterials occupying a different region of physicochemical
space7,9,16, some of which are dosed parenterally or topically and
are more polar and have high aqueous solubility.8
Recently the physicochemical space of antibacterials has been
classiﬁed based on bacteria classes by O’Shea et al.7 For 147 active
antibacterial compounds analysed, it was shown that Gram-posi-
tive and Gram-negative antibacterials have different physicochem-
ical properties; for example, the mean molecular weights were 813
and 414, respectively. These ﬁndings were attributed to the differ-
ent cell-wall architecture of the two bacterial classes. Both classes
contain an inner membrane and a peptidoglycan layer. In addition,
Gram-negative bacteria consist of an outer less permeable polar
membrane and promiscuous efﬂux pumps.7,10 The ﬁrst attempt
to classify antibacterials agents based on target-classes was made
by Brown et al.10 They showed that physical properties of HTS
antibacterial hits were associated with their respective targets.
For example, in Pseudomonas aeruginosa, compounds binding to
the hydrophobic pocket of UDP-(3-O-(R-hydroxymyristoyl))-N-
acetylglucosamine deacetylase (LpxC) were generally hydrophobic.
This analysis focused mostly on Gram-negative HTS hits and con-
clusions were drawn based on one bacterial organism. On the other
hand, Leeson et al.17 reported that for most human drugs,
lipophilicity was comparable indicating the importance of this
parameter irrespective of the drug’s target, but a different pattern
was observed for several anti-infectives including antibacterials.
The scope of our current work is based on the hypothesis that
the different physicochemical properties of antibacterial agents
may also be related to the nature and type of their molecular tar-
gets responsible for drug efﬁcacy. Here we focus on differences in
the surface properties of the binding pockets for bacterial-proteins
(where the molecular target is either simple protein, protein fam-
ilies or protein–protein complex) and riboproteins (where the
molecular target is an RNA or RNA/protein species). We analysed
the physicochemical properties of about 2000 compounds consist-
ing of world-wide approved antibacterial agents targeting eitherproteins or riboproteins and non-antibacterials targeting speciﬁ-
cally human proteins, using analysis routines implemented in
Pipeline Pilot (Biovia).18 The goal was to determine the association
of physicochemical properties of antibacterials and their target-
class. Bioactive compounds that target human proteins generally
fall within the established parameter range for Lipinski ‘drug-like’
compounds and were therefore used as comparator benchmarks.
2. Methods
2.1. Source of target-ligand pairs
All compound and target data used in this work was obtained
from the ChEMBL database19,20 an Open Access database of bioac-
tive small molecules and activity data. ChEMBL version 19, holds
1.4 million distinct bioactive small molecules, 10 thousand
annotated targets, and more than 12 million activities. The data
has been manually extracted from about 57,000 publications and
curated by experienced chemistry and biology curators.
2.2. Drugs and their targets dataset
A dataset containing more than 1700 drugs including bioactiv-
ity information was retrieved from ChEMBL version 19 using a
Pipeline Pilot protocol (Biovia).18 An SQL query was written to pull
out information for distinct approved drugs and their annotated
targets. The criteria used included extraction of simple drug mole-
cules that were approved drugs, and had a speciﬁed therapeutic
application (therapeutic ﬂag 1).
2.3. Physicochemical properties and analysis
The dataset was split into two, the ﬁrst subset consisted of
drugs that act through human targets and the second one had
those that act through bacterial targets. The bacterial target subset
was further divided into two speciﬁc sub-subsets; namely (i) bac-
terial-proteins (where the molecular target is a simple molecule,
protein family or a protein–protein complex) and riboproteins
(where the molecular target is an RNA or RNA/protein species).
We identiﬁed no possibility to split the human set into RNA and
protein subsets, since no evidence of speciﬁc RNA-class targets
were identiﬁable in ChEMBL. For each target, duplicate molecules
were ﬁltered from these three sets, so that in each only unique
drug molecules were analysed (Fig. 1). Various simple physico-
chemical properties including molecular weight (Mwt), a logP,
logD, polar surface area (PSA), H-bond donors and H-bond accep-
tors were calculated using the standard components in Pipeline
Pilot. Analysis of the physicochemical properties of ‘human pro-
teins’, ‘bacterial proteins’ and ‘bacterial riboproteins’ ligand sets
was performed using Vortex from Dotmatics Ltd (http://www.dot-
matics.com/products/vortex/).
3. Results and discussion
A total of 1713 target-ligand pairs of drugs that target proteins
from 42 organisms, including human, bacteria, plasmodia, viruses,
was mined from the ChEMBL database (www.ebi.ac.uk/chembl).20
Human target-ligand pairs constituted 82% (1419 pairs) of the
set, bacteria pairs made up 11% (187 pairs). Comparison of the
physicochemical properties of antibacterials indicates a relation-
ship between the compound properties and the class of proteins
they target.
The target-ligand dataset was initially divided into four classes
made up of (i) single proteins, for example bacterial enoyl-[acyl-
carrier-protein] reductase, a target for one of the ﬁrst-line anti-
Figure 1. A workﬂow used to mine target-ligand data from the ChEMBL version 19. The dataset was split into three subsets containing ligands targeting human protein,
bacterial-protein and bacterial riboproteins targets.
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proteins with high sequence similarity, for example, bacterial peni-
cillin binding proteins (PBPs) modulated by drugs like doripenem;
(iii) protein complexes, for example, topoisomerase IV targeted by
ﬂuoroquinolones, such as gatiﬂoxacin or (iv) RNA–protein com-
plexes (riboproteins), for example, the 70S ribosome that contains
a large number of structurally distinct binding sites for approved
drugs, such as erythromycin. This classiﬁcation indicated that
about three quarters of the approved antibacterials act upon single
proteins, protein families and other protein complexes and only
25% target ribosomes (Table 1). A similar analysis of a set of
approved antibacterials was retrieved using the WHO Anatomical
Therapeutic Chemical (ATC)21 classiﬁcation codes J01 and J04
(available from http://www.whocc.no/atc_ddd_index/). The letter
J indicates that a drug is an anti-infective for systematic use, J01
covers antibacterials for systematic use, and J04 antimycobacteri-
als. The analysis of WHO ATC drugs (a broader set than the FDA-
approved core of ChEMBL drugs) revealed comparable proportions
as 69% antibacterial drugs target bacterial-proteins whilst 21%
target riboproteins as shown in Figure 2.
There is a general and signiﬁcant increase in the average of each
property from single proteins ligands to compounds targeting ribo-
proteins (Table 1). The single protein class is mainly targeted by
sulfonamides that are small and on average have properties within
the typical range of oral drugs. The same is true for penicillins and
ﬂuoroquinolones, nonetheless the riboproteins-targeted ligands
occupy a different physicochemical space characterised by higher
molecular weight (average Mwt = 566), high polarity (PSA of193), and with number of H-bond acceptor and donors larger than
the ‘drug-like’ threshold. In contrast, the human protein set of
ligands is small (average Mwt <400), slightly lipophilic, and less
polar and as discussed above, none of these are known to target
nucleic-acid complexes.
3.1. Comparison of physicochemical properties of bacterial-
protein and riboprotein ligands
3.1.1. Molecular weight
A comparison of the simple but fundamental property, molecu-
lar weight, of antibacterials, indicates that about 80% (30/38) of the
drugs whose modes of action involve riboproteins (ribosomes)
(orange) have Mwt >500 Da and some of the ligands e.g. quin-
upristin, have Mwt over 1000 Da. Whereas 87% (105/120) of
unique bacterial protein ligands (green) had Mwt <500 Da, a region
also occupied by about 93% (900/966) of ligands for human pro-
teins (grey) (Fig. 3). Most bacterial protein targeting molecules
occupy the same physicochemical space (Mwt <500 Da)10 as orally
administered drugs from other therapeutic areas even though the
medians of molecular weights of bacterial and human protein
modulators differ by 40 units, (380 and 340, respectively). The
slight increase in molecular weights for bacterial protein ligands
could be attributed to the presence of the rifamycins, such as
rifampicin (Mwt: 822.94 Da), that target DNA-directed RNA poly-
merase22 and contain a privileged macrocyclic ring. Further analy-
sis of Figure 3 indicates that there is no normal distribution the
Mwts. From Wilcoxon test, at signiﬁcant level p = 0.05, it is
Table 1
Classes of bacterial targets and the mean property of their ligands
Target-class No. of compds Examples of compd class Molecular weight (Da) A logP PSA # H-bond donors # H-bond acceptors
Single proteins 33
Sulphonamides
NH
S
O
O
H2N
R
261 0.50 101 2 5
Protein families 62
Penicillins
R
NH
S
CH3
CH3
N
O
O
HO
445 1.44 190 2 9
Protein complex 24
Fluoroquinolones
R3
F
O
N
R4
O
OH
R2
R1
312 0.44 79 2 6
Riboprotein 38
Tetracyclines
CH3
N
H3C
OH
OH
O
OH
O
NH2OOH
R1
R2 R4R3
566 0.31 193 5 11
Figure 2. Results for the ATC classiﬁcation of antibacterials indicating that most drugs target bacterial-proteins.
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bacterial sets (p = 0.57). A p-value greater than 0.05 conﬁrms the
null hypothesis, which states that there is no signiﬁcant difference
the medians of the two sets.On the contrary, the set of riboprotein ligands displayed a med-
ian 500 Da and the molecular weight increases gradually from
120 to 1022 Da, as shown in Figure 3. The smallest putative
ligand, pyrazinamide (Mwt = 123 Da)23,24, whereas the largest
Figure 3. (A) Distribution of molecular weights (Mwt) for riboprotein, human and bacterial-protein targeting drugs. (B) The distribution of molecular weight of bacterial-
protein and bacterial-riboprotein compounds.
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blocks the translation of mRNA into protein.25 The calculated
p-values from the Wilcoxon test for Mwt distribution of
human/riboprotein sets (p = 4.68e–08), and bacterial/riboprotein
sets (p = 6.42e–04) indicate that riboprotein targeted compounds
occupy a different molecular weight space. Based on the molecular
weights the riboprotein targeting compounds constitute two major
classes of compounds: small molecular size group made up pri-
marily of tetracyclines (400 > Mwt < 500), and a large molecular
size group consisting mostly macrolides and aminoglycosides.
3.1.2. Lipophilicity and polarity
Antibacterials are collectively classiﬁed as large and polar com-
pounds with relatively low lipophilicity.7,9 The 2D distributions in
Figure 4A of calculated a logP values and Mwt indicated that bac-
terial-protein and bacterial-riboprotein modulators are less lipo-
philic than human protein ligands. From the statistical analysis,
it can be suggested that there is no signiﬁcant value between the
bacterial and riboprotein datasets (p = 0.63) but signiﬁcant differ-
ence is displayed by the human/bacteria and human/riboprotein
sets (p <0.05). However, riboprotein ligands displayed much lower
lipophilicity with approximately 19% of the total compounds
showing a logP >2 (Fig. 4) and low calculated logD values
(Supporting information, Fig. S1). Compounds with the lowest
lipophilicity were three aminoglycosides, neomycin
(Mwt = 614.16 Da, a logP = 8.96), amikacin (Mwt = 585.6 Da,a logP = 8.43), and paromomycin (Mwt = 615.63 Da,
a logP = 8.67) that bind to pockets in the 30S subunit of the bac-
terial ribosome. Aminoglycosides form an important class of
antibacterials used to treat a variety of infections but display poor
attributes for oral absorption, hence, they are mainly administered
intravenously, for example, amikacin. Paromomycin, formerly used
to treat intestinal infections has been repositioned and is currently
used as an injectable in chemotherapy of protozoal visceral leish-
maniasis in India.26
An opposite but similar trend was revealed by the calculate PSA
values where most antibacterial compounds were generally highly
polar. Approximately 92% of the human protein targeting drugs
exhibited PSA values below 140 Å2, a recommended limit for good
oral absorption.15 Bacterial-protein modulators displayed moder-
ate polarity (45% compounds have PSA <130 Å2), whilst 80% of
riboprotein ligands showed high polarity (PSA >130 Å2) indicating,
once again, a difference between the two target-classes.
Statistically all three datasets have signiﬁcant difference in PSA
distribution, since the calculated Wilcoxon p-values were less than
0.05. Further analysis of the results revealed that there was signif-
icant correlation between a logP and logD (r2 = 0.72), and Mwt and
PSA (r2 = 0.91) for bacterial-protein ligands, whereas low or poor
correlation is displayed by riboproteins target properties except
for logD and PSA (r2 = 0.98) (Supporting information, Fig. S1).
This shows that increase in molecular weight of the ligands does
not directly inﬂuence lipophilicity across both target-classes as
Figure 4. Distribution of (A) aLogP, and (B) PSA against molecular weight for
human, bacterial-proteins and bacterial-riboproteins.
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targeted drugs, for small antibacterials, polarity of a compound
increases with increase in the molecular weight.
3.1.3. Riboprotein binding drugs
Following the landmark determination of complete, high-reso-
lution structures27,28 of the bacterial ribosome, for which a Nobel
prize was awarded, there is now detailed understanding of distinct
drug binding sites, resistance mechanisms, and the possibility to
design new agents using structural approaches. The ribosomes
consist of two subunits—30S inhibited by tetracyclines and the
aminoglycosides, and the 50S subunit, acted upon by, for example
macrolides, Ribosome binding pockets are generally large with
width greater than 10 Å and provide nucleotide rich environments
that are highly polar due to presence of the phosphate groups in
the RNA backbone, and the higher fractional content of polar N
and O atoms in the nucleotide bases compared to amino acid side
chains, H-bond acceptor and donor atoms, in addition to
hydrophobic moieties.29,30 Consequently, tetracyclines (Support
information, Table S2) are made up of fused ring systems with
highly polar groups on one side that form a dense network of
hydrogen bonds with a magnesium ion and nucleotide residues
found in the primary site of 30S ribosome.29 The hydrophobic edge
of the drug molecule is conducive for hydrophobic interactions or
stacking interactions with the aromatic rings of the binding site
residues. Similarly, macrolides, for example, erythromycin, consistof the lactone ring where C5 atom is bonded to a sugar residues at
C5 atom. Ribosome-inhibitor interactions are enhanced through
hydrophobic interactions with the lactone ring and hydrophilic
interactions involving the sugar substructures.30 This illustrates
that for strong and effective binding to their targets, the designed
small molecules should match the architecture of the binding sites
of their respective targets. Normally, hydrophobic molecules bind
to hydrophobic binding sites through dispersion forces and pi–pi
interactions for example. On the other hand, large and polar mole-
cules would form hydrogen bonds, ionic interactions and salt-
bridges with the respective binding site residues. Accordingly,
riboprotein targeting compounds have exceptional physicochemi-
cal properties that favour binding to the main ribosome binding
sites. These observations highlight the fact that the observed dif-
ference in molecular properties for the two classes of antibacterial
drugs examined here (protein or riboproteins targeted) are due to
the distinct differences in binding site properties driven by differ-
ences in composition and polarity of the underlying constituent
biopolymers.
4. Conclusion
Most antibacterials that act via bacterial protein targets have
physicochemical properties within the classical range for oral
human protein targeted drugs, whereas a majority of the bacterial
riboprotein-targeted drugs fall beyond the speciﬁed upper limit of
the Rule of Five—500 Da (Mwt), and are more polar. We propose
therefore that it is useful to consider antibacterial compounds as
falling into three classes; (i) bacterial protein-targeted ligands
(small and moderately lipophilic), (ii) riboprotein-targeted ligands
(large molecular sizes and high polarity and these generally violate
the ‘Rule of Five’), and (iii) non-gene product-targeted ligands (e.g.,
compounds such as gramicidin). We believe that this treatment
would add value to the future discovery and optimisation of
antibacterials, and that combining target-class and binding site
information with appropriate physicochemical parameters models
would facilitate drug discovery, especially during screening ﬁle
design and acquisition, target prediction, hit identiﬁcation and lead
optimisation stages. Finally, the extrapolation of antibacterial drug
property proﬁles derived independent of target class and applying
them to bacterial protein targets, as typically found in genetic
knockout and bioinformatics studies may well decrease the pro-
ductivity of antibacterial drug discovery. Conversely collection of
compounds that are likely to bind to riboproteins surfaces may
well be an excellent strategy for discovery of novel ribosome mod-
ulators, an already comprehensively validated antibacterial drug
target.
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